IBS Biomarkers for IBS: ready for prime time?

被引：11

作者：

Barbara, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, Dept Med & Surg Sci, St Orsola Malpighi Hosp, I-40138 Bologna, Italy

来源：

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2015年 / 12卷 / 01期

关键词：

IRRITABLE-BOWEL-SYNDROME; MICROBIOTA;

D O I：

10.1038/nrgastro.2014.217

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Evidence is mounting that molecular mechanisms underlie gut dysfunction and symptom generation in IBS. Although it is still an uphill struggle, this mounting evidence is a good starting point for the discovery of one or more IBS biomarkers.

引用

页码：9 / +

页数：2

共 10 条

[1] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[2] Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome [J].

Barbara, G ;

Stanghellini, V ;

De Giorgio, R ;

Cremon, C ;

Cottrell, GS ;

Santini, D ;

Pasquinelli, G ;

Morselli-Labate, AM ;

Grady, EF ;

Bunnett, NW ;

Collins, SM ;

Corinalidesi, R .

GASTROENTEROLOGY, 2004, 126 (03) :693-702

[3] Biomarkers in IBS: when will they replace symptoms for diagnosis and management? [J].

Barbara, Giovanni ;

Stanghellini, Vincenzo .

GUT, 2009, 58 (12) :1571-1575

[4]

Camilleri M., 2012, Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc

[5] Peripheral Mechanisms in Irritable Bowel Syndrome [J].

Camilleri, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (17) :1626-1635

[6] An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota [J].

Jeffery, Ian B. ;

O'Toole, Paul W. ;

Ohman, Lena ;

Claesson, Marcus J. ;

Deane, Jennifer ;

Quigley, Eamonn M. M. ;

Simren, Magnus .

GUT, 2012, 61 (07) :997-1006

[7] A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads [J].

Jones, M. P. ;

Chey, W. D. ;

Singh, S. ;

Gong, H. ;

Shringarpure, R. ;

Hoe, N. ;

Chuang, E. ;

Talley, N. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (04) :426-437

[8] Use of serum biomarkers in a diagnostic test for irritable bowel syndrome [J].

Lembo, A. J. ;

Neri, B. ;

Tolley, J. ;

Barken, D. ;

Carroll, S. ;

Pan, H. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (08) :834-842

[9] Burden of Gastrointestinal Disease in the United States: 2012 Update [J].

Peery, Anne F. ;

Dellon, Evan S. ;

Lund, Jennifer ;

Crockett, Seth D. ;

McGowan, Christopher E. ;

Bulsiewicz, William J. ;

Gangarosa, Lisa M. ;

Thiny, Michelle T. ;

Stizenberg, Karyn ;

Morgan, Douglas R. ;

Ringel, Yehuda ;

Kim, Hannah P. ;

Dibonaventura, Marco Dacosta ;

Carroll, Charlotte F. ;

Allen, Jeffery K. ;

Cook, Suzanne F. ;

Sandler, Robert S. ;

Kappelman, Michael D. ;

Shaheen, Nicholas J. .

GASTROENTEROLOGY, 2012, 143 (05) :1179-+

[10] Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples From Patients With Irritable Bowel Syndrome [J].

Rajilic-Stojanovic, Mirjana ;

Biagi, Elena ;

Heilig, Hans G. H. J. ;

Kajander, Kajsa ;

Kekkonen, Riina A. ;

Tims, Sebastian ;

de Vos, Willem M. .

GASTROENTEROLOGY, 2011, 141 (05) :1792-1801

← 1 →